NASDAQ:BIOL - BIOLASE Stock Price, Forecast & News

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

BIOLASE shares reverse split on Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 10th 2018. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 20 shares after the split.

BIOLASE Inc (NASDAQ:BIOL) issued its quarterly earnings results on Wednesday, November, 6th. The medical technology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.13. The medical technology company had revenue of $8.65 million for the quarter. BIOLASE had a negative return on equity of 313.64% and a negative net margin of 52.13%. View BIOLASE's Earnings History.

BIOLASE is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for BIOLASE.

4 brokers have issued 1-year price objectives for BIOLASE's stock. Their forecasts range from $2.00 to $3.00. On average, they expect BIOLASE's stock price to reach $2.50 in the next year. This suggests a possible upside of 223.4% from the stock's current price. View Analyst Price Targets for BIOLASE.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIOLASE.

Press coverage about BIOL stock has trended very positive recently, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BIOLASE earned a media sentiment score of 3.1 on InfoTrie's scale. They also assigned news headlines about the medical technology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for BIOLASE.

Some companies that are related to BIOLASE include Straumann (SAUHF), DENTSPLY SIRONA (XRAY), Sartorius (SARTF), SmileDirectClub (SDC), Biomerica (BMRA) and Remedent (REMI).

Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Magnachip Semiconductor (MX), Fluidigm (FLDM), NovaBay Pharmaceuticals (NBY), Vuzix (VUZI), Athersys (ATHX), Allena Pharmaceuticals (ALNA), Biocept (BIOC) and CTI BioPharma (CTIC).

BIOLASE's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Archon Capital Management LLC (8.65%) and Perkins Capital Management Inc. (4.26%). Company insiders that own BIOLASE stock include Garrett Sato, John R Beaver, Jonathan T Md Lord, Larry N Feinberg and Todd Norbe. View Institutional Ownership Trends for BIOLASE.

BIOL stock was purchased by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc. and Archon Capital Management LLC. Company insiders that have bought BIOLASE stock in the last two years include Garrett Sato, John R Beaver, Jonathan T Md Lord, Larry N Feinberg and Todd Norbe. View Insider Buying and Selling for BIOLASE.

Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BIOL stock can currently be purchased for approximately $0.77.

BIOLASE has a market capitalization of $23.93 million and generates $46.15 million in revenue each year. The medical technology company earns $-21,520,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. BIOLASE employs 190 workers across the globe.View Additional Information About BIOLASE.

The official website for BIOLASE is http://www.biolase.com/.

BIOLASE's mailing address is 4 Cromwell, Irvine CA, 92618. The medical technology company can be reached via phone at 949-361-1200 or via email at [email protected]